Sushil Patel's Insider Trades & SAST Disclosures
Sushil Patel's most recent trade in Replimune Group Inc was a trade of 250,000 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on April 1, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Sushil Patel.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Replimune Group Inc | Sushil Patel | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 250,000 | 250,000 | - | - | Employee Stock Option (right to buy) | |
| Replimune Group Inc | Sushil Patel | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 166,667 | 368,681 (1%) | 0% | 0 | Common Stock | |
| Plumas Bancorp. | Sushil A. Patel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2025 | 1,011 | 2,385 (0%) | 0% | - | Common Stock | |
| Plumas Bancorp. | Sushil A. Patel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2025 | 1,011 | 0 | - | - | Restricted stock units | |
| Replimune Group Inc | Sushil Patel | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 12.42 per share. | 16 Dec 2024 | 10,000 | 202,014 (0%) | 0% | 12.4 | 124,200 | Common Stock |
| Revolution Medicines Inc | Sushil Patel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.84 per share. | 31 Oct 2024 | 5,000 | 24,948 (0%) | 0% | 24.8 | 124,200 | Common Stock |
| Revolution Medicines Inc | Sushil Patel | Director | Sale of securities on an exchange or to another person at price $ 54.14 per share. | 31 Oct 2024 | 5,000 | 19,948 (0%) | 0% | 54.1 | 270,715 | Common Stock |
| Revolution Medicines Inc | Sushil Patel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2024 | 5,000 | 13,400 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Sushil Patel | Director | Sale of securities on an exchange or to another person at price $ 44.00 per share. | 09 Jul 2024 | 2,155 | 19,948 (0%) | 0% | 44 | 94,820 | Common Stock |
| Revolution Medicines Inc | Sushil Patel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jul 2024 | 2,155 | 32,490 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Sushil Patel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.80 per share. | 09 Jul 2024 | 2,155 | 22,103 (0%) | 0% | 16.8 | 36,204 | Common Stock |
| Revolution Medicines Inc | Sushil Patel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 16,700 | 16,700 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Sushil Patel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 15,955 | 15,955 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Sushil Patel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 4,800 | 20,500 (0%) | 0% | 0 | Common Stock | |
| Revolution Medicines Inc | Sushil Patel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 4,248 | 19,948 (0%) | 0% | 0 | Common Stock | |
| Plumas Bancorp. | Sushil A. Patel | Director | Purchase of securities on an exchange or from another person at price $ 35.65 per share. | 20 May 2024 | 1,126 | 1,226 (0%) | 0% | 35.7 | 40,142 | Common Stock |
| Plumas Bancorp. | Sushil A. Patel | Director | Purchase of securities on an exchange or from another person at price $ 35.49 per share. | 20 May 2024 | 100 | 100 (0%) | 0% | 35.5 | 3,549 | Common Stock |
| Plumas Bancorp. | Sushil A. Patel | Director | Purchase of securities on an exchange or from another person at price $ 35.64 per share. | 20 May 2024 | 50 | 1,374 (0%) | 0% | 35.6 | 1,782 | Common Stock |
| Plumas Bancorp. | Sushil A. Patel | Director | Purchase of securities on an exchange or from another person at price $ 35.50 per share. | 20 May 2024 | 50 | 1,276 (0%) | 0% | 35.5 | 1,775 | Common Stock |
| Plumas Bancorp. | Sushil A. Patel | Director | Purchase of securities on an exchange or from another person at price $ 35.56 per share. | 20 May 2024 | 48 | 1,324 (0%) | 0% | 35.6 | 1,707 | Common Stock |
| Replimune Group Inc | Sushil Patel | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 6.47 per share. | 16 May 2024 | 20,194 | 212,014 (0%) | 0% | 6.5 | 130,655 | Common Stock |
| Revolution Medicines Inc | Sushil Patel | Director | Sale of securities on an exchange or to another person at price $ 37.00 per share. | 10 Apr 2024 | 2,155 | 15,700 (0%) | 0% | 37 | 79,735 | Common Stock |
| Revolution Medicines Inc | Sushil Patel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Apr 2024 | 2,155 | 34,645 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Sushil Patel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.80 per share. | 10 Apr 2024 | 2,155 | 17,855 (0%) | 0% | 16.8 | 36,204 | Common Stock |
| Replimune Group Inc | Sushil Patel | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 250,000 | 250,000 | - | - | Employee Stock Option (right to buy) | |
| Replimune Group Inc | Sushil Patel | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 83,335 | 232,208 (0%) | 0% | 0 | Common Stock | |
| Plumas Bancorp. | Sushil Patel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2024 | 1,011 | 0 | - | - | Restricted stock units | |
| Replimune Group Inc | Sushil Patel | Chief Strategy Officer | Sale of securities on an exchange or to another person at price $ 24.11 per share. | 13 Jun 2023 | 5,145 | 149,426 (0%) | 0% | 24.1 | 124,046 | Common Stock |
| Replimune Group Inc | Sushil Patel | Chief Strategy Officer | Sale of securities on an exchange or to another person at price $ 23.44 per share. | 13 Jun 2023 | 553 | 148,873 (0%) | 0% | 23.4 | 12,962 | Common Stock |
| Revolution Medicines Inc | Sushil Patel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 18,400 | 18,400 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Sushil Patel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 5,200 | 15,700 (0%) | 0% | 0 | Common Stock | |
| Replimune Group Inc | Sushil Patel | Chief Strategy Officer | Sale of securities on an exchange or to another person at price $ 18.05 per share. | 16 May 2023 | 15,575 | 154,571 (0%) | 0% | 18.1 | 281,129 | Common Stock |
| Replimune Group Inc | Sushil Patel | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 60,000 | 60,000 | - | - | Employee Stock Option (right to buy) | |
| Replimune Group Inc | Sushil Patel | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 40,000 | 170,146 (0%) | 0% | 0 | Common Stock | |
| Revolution Medicines Inc | Sushil Patel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 36,800 | 36,800 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Sushil Patel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 10,500 | 10,500 (0%) | 0% | 0 | Common Stock | |
| Replimune Group Inc | Sushil Patel | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 14.59 per share. | 16 May 2022 | 10,687 | 130,146 (0%) | 0% | 14.6 | 155,923 | Common Stock |
| Replimune Group Inc | Sushil Patel | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 78,750 | 78,750 | - | - | Employee Stock Option (right to buy) | |
| Replimune Group Inc | Sushil Patel | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 52,500 | 140,833 (0%) | 0% | 0 | Common Stock | |
| Replimune Group Inc | Sushil Patel | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2021 | 125,000 | 125,000 | - | - | Employee Stock Option (right to buy) | |
| Replimune Group Inc | Sushil Patel | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2021 | 88,333 | 88,333 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges